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Abstract
Objective An association between susceptibility to inflam-
matory bowel disease (IBD) and polymorphisms of both the
tyrosine kinase 2 gene (TYK2) and the signal transducer
and activator of transcription 3 gene (STAT3) was examined
in a Japanese population in order to identify the genetic
determinants of IBD.
Methods The study subjects comprised 112 patients with
ulcerative colitis, 83 patients with Crohn’s disease (CD), and
200 healthy control subjects. Seven tag single-nucleotide
polymorphisms(SNPs) inTYK2 and STAT3 were detected by
PCR-restriction fragment length polymorphism.
Results The frequencies of a C allele and its homozygous
C/C genotype at rs2293152 SNP in STAT3 in CD patients
were significantly higher than those in control subjects
(P=0.007 and P=0.001, respectively). Furthermore, out of
four haplotypes composed of the two tag SNPs (rs280519
and rs2304256) in TYK2, the frequencies of a Hap 1
haplotype and its homozygous Hap 1/Hap1 diplotype were
significantly higher in CD patients in comparison to those
in control subjects (P=0.023 and P=0.024, respectively). In
addition, the presence of both the C/C genotype at
rs2293152 SNP in STAT3 and the Hap 1/Hap 1 diplotype
of TYK2 independently contributes to the pathogenesis of
CD and significantly increases the odds ratio to 7.486 for
CD (P=0.0008).
Conclusion TYK2 and STAT3 are genetic determinants of
CD in the Japanese population. This combination polymor-
phism may be useful as a new genetic biomarker for the





Idiopathic inflammatory bowel disease (IBD) is a multifac-
torial disorder characterized by chronic and relapsing
inflammation specific to the gastrointestinal tract, thus
resulting in intestinal malabsorption, mucosal immune
system abnormalities, and exaggerated inflammatory
responses [1–5]. IBD has two main subtypes, namely
ulcerative colitis (UC) and Crohn’s disease (CD). Although
the precise etiology remains unknown, several environmen-
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DOI 10.1007/s10875-009-9320-xtal factors, such as commensal bacteria, food antigens, and
smoking, as well as multiple genetic factors may contribute
to the occurrence and development of IBD [1–5]. Genome-
wide linkage-based family studies, candidate gene-based
association studies, and large-scale genome-wide associa-
tion (GWA) studies using single-nucleotide polymorphisms
(SNPs) have shown possible IBD susceptibility genes and
chromosomal loci [6–10].
IBD is involved in a complex interplay of innate and
adaptive immune cells, including lymphocytes, macro-
phages, and dendritic cells. In such a setting, alterations in
cytokine synthesis and cytokine signaling pathways are
attributed to the pathogenesis of IBD [1–5]. GWA studies
have recently indicated that the multiple genes implicated in
the interleukin 23 (IL-23) and its receptor (IL23R) signaling
pathway are associated with susceptibility to CD as well as
UC [6–12]. For example, IL-23, IL23R, interleukin 12
precursor (IL12B), interleukin 12 receptor (IL12R), the
Janus kinase (JAK) families, and the signal transducers and
activators of transcription (STAT) families belong to a gene
network in the IL-23/IL23R signaling pathway [13],
implying that a subset of these genes can play a central
role in the pathogenesis of IBD and may function as a key
conductor of innate and adaptive inflammatory responses at
multiple levels in the intestinal mucosa of IBD patients.
IL-23 as well as JAK2 [9, 14]a n dSTAT3 [9, 12, 14]a r e
associated with susceptibility to CD. These genes are
involved in a gene network in the IL23/IL23R signaling
pathway. JAK2 has been recently identified as a CD
susceptibility gene in a meta-analysis of GWA data [9, 14]
but not by any single-marker association studies on CD.
Likewise, tyrosine kinase 2 (TYK2), which is a member of
the JAK families located in β1 subunit of IL12 receptor
(IL12RB1) [4, 15–17] and in gp130 of interleukin 6
receptor (IL6R) [18], is also identified as a CD suscepti-
bility gene by the meta-analysis [10] but did not reach
significance by single-marker association studies. Further-
more, TYK2 is activated via signaling from a broader
range of cytokine receptors and induces phosphorylation,
homodimerization, and nuclear translocation of STAT3
[15–19], thus resulting in several gene transcriptions and
leading to IL-23-induced production of IL-17, a pro-
inflammatory cytokine in natural killer cells, natural killer
Tc e l l s ,C D 4
+ T cells, and CD8
+ T cells [20–22]. This
signaling cascade also plays a role in the differentiation of
CD4
+ (naive) T cells into Th17 cells [17, 20–22], which is
involved in the first line of host defense by controlling
immune responses [22].
Therefore, we performed a candidate gene-based
association study by selecting TYK2 and STAT3 as
candidate genes. The purpose of this study was to
investigate whether SNPs and their combination poly-
morphisms, which are referred to as haplotypes, in TYK2
and STAT3 are also associated with susceptibility to IBD
in a Japanese population and whether such polymorphisms




The study subjects were Japanese who were unrelated to
one another. The subjects included 112 patients with
UC, 83 patients with CD, and 200 gender-matched,
healthy volunteers as control subjects. IBD patients
were enrolled from eight general hospitals in Nagasaki,
Japan from October 2003 to October 2008. The clinical
characteristics of the subjects at the end point of this
study are shown in Table I. The study protocol was
approved by the Committee for Ethical Issue dealing with
the Human Genome and Gene Analysis at Nagasaki
University, and written informed consent was obtained
from each subject.
The diagnosis of IBD was made based on the
endoscopic, radiological, histological, and clinical criteria
e s t a b l i s h e db yb o t ht h eW o r l dH e a l t hO r g a n i z a t i o n
Council for International Organizations of Medical Scien-
ces and the International Organization for the Study of
Inflammatory Bowel Disease [23–25]. Patients with
indeterminate colitis, multiple sclerosis, systemic lupus
erythematosus, or any other diagnosed autoimmune dis-
eases were excluded from this study.
Patients with UC were classified into subgroups
according to age at onset (≤40 or ≥40 years), extension
of disease (proctitis, left-sided colitis, or pancolitis),
disease severity (mild, moderate, or severe), and disease
activity (active or inactive) (Table I). Likewise, patients
with CD were classified into subgroups according to age
at onset (≤40 or ≥40 years), the location of lesions (ileal,
ileocolonic, colonic, or isolated upper), disease severity
(mild, moderate, or severe), disease activity (active or
inactive), and the behavior of disease (stricturing, pene-
trating, or perianal; Table I). The location and extension of
UC and CD, disease severity of UC and CD, and behavior
of CD were stratified in accordance with the Montreal
classification [26] with slight modification. A high clinical
activity index (CAI≥5) for UC [27] and a high Crohn’s
disease activity index (CDAI≥150) [28] were regarded as
active-phase patients.
Preparation of Genomic DNA
Genomic DNA was extracted from a whole blood sample
from each subject using a DNA Extractor WB-Rapid Kit
816 J Clin Immunol (2009) 29:815–825(Wako, Osaka, Japan) according to the manufacturer’s
protocol.
Sources of the Candidate Genes and Their Polymorphisms
All of SNPs in STAT3 (GenBank accession number,
AY572796; MIM 102582) located on chromosome 17q21
[29]a n dTYK2 (GenBank accession number, AY549314;
MIM 176941) located on chromosome 19p13.2 [30]w e r e
obtained using data available on the International HapMap
Web site [31]. Candidate tag SNPs were selected with
priority in a minor allele frequency of more than 5%.
Subsequently, linkage disequilibrium blocks and geno-
typed tag SNPs among the candidate tag SNPs were
determined using the iHAP software program [32]. The
gene structure and positions of the genotyped tag SNP
sites in STAT3 and TYK2 are shown in Figs. 1 and 2,
respectively.
Determination of Three SNPs in STAT3
Three SNPs, rs8074524 in intron 3, rs2293152 in intron 11,
and rs957970 in intron 23, were selected as genotyped tag
SNPs (Fig. 1) and were subsequently analyzed by poly-
merase chain reaction (PCR)-restriction fragment length
polymorphism (RFLP). The polymorphic region was
amplified by PCR with a GeneAmp PCR System 9700
thermal cycler (Applied Biosystems, Foster City, CA, USA)
using 25 ng of genomic DNA in a 25-µl reaction mixture
containing 0.8× GoTaq Green master mix (Promega,
Madison, WI, USA) and 15 pmol each of the following
primers: forward primer 5′-GTCTGGAAAGCTC
CATCTGC-3′ and reverse primer 5′-AGAGGCCAGAT
TAGTGCTGG-3′ for rs8074524; forward primer
5′-TCCCCTGTGATTCAGATCCC-3′ and reverse primer
5′-CATTCCCACATCTCTGCTCC-3′ for rs2293152; and
forward primer 5′-CTGGGCTCAAGTGATCTTCC-3′ and
Characteristics Patients with Control subjects
UC CD
Number 114 83 200
Age, mean±SD (years) 44.2±16.7* 34.3±12.5 32.5±11.2
Age range (years) 14–83 17–75 20–60
Male/female (%) 59/55 (51.7/48.3) 50/33 (60.2/39.8) 126/74 (62.5/37.5)
Age at onset
≤40 years 39 11
























Table I The Clinical Character-
istics of Study Subjects
SD standard deviation
*P<0.01 in comparison to con-
trol subjects
aNumber of the affected patients
with CD
J Clin Immunol (2009) 29:815–825 817reverse primer 5′-GTACTCATCGCCCTCCATTG-3′ for
rs957970. The amplification protocol comprised initial
denaturation at 95°C for 2 min, followed by 30 cycles of
denaturation at 95°C for 30 s, annealing at 62°C for 30 s,
and extension at 72°C for 30 s and final extension at 72°C
for 5 min. The PCR products were digested with restriction
enzyme, Hpa II (Takara Bio Inc., Kyoto, Japan) for
rs8074524 and rs2293152; Xsp I (Takara Bio Inc.) for
rs957970. The digests were separated by electrophoresis on
a 2% agarose gel (Nacalai Tesque, Kyoto, Japan) and
visualized with an ultraviolet transilluminator (Alpha
Innotech Co., San Leandro, CA, USA) after ethidium
bromide (Nacalai Tesque) staining.
Determination of Four SNPs in TYK2
Four genotyped tag SNPs in TYK2, rs280496 in intron 3,
rs280519 in intron 14, rs2304256 in intron 18, and
rs280523 in intron 20 (Fig. 2), were analyzed by PCR-
RFLP using 15 pmol each of the following primers:
Fig. 1 Locations of the genotyped tag SNP sites in STAT3 in the
International HapMap (upper) and iHap (lower) data. The horizontal
bars in the middle indicate the genomic sequence of STAT3. Blue
vertical bars indicate the positions of all SNP sites. Yellow rectangles
represent the positions of linkage disequilibrium blocks. A list and the
locations of candidate tag SNPs are shown in the lower right position
using Haploview 4.0 software. Red inverted triangles indicate the
genotyped tag SNPs sites in this study, and their names are presented
above each inverted triangle
818 J Clin Immunol (2009) 29:815–825forward primer 5′-CGGGGTGATATGCTCATTGG-3′ and
reverse primer 5′-CAACGTGCTGCTGGACAACG-3′ for
rs280496; forward primer 5′-CCGCCATGGTGAAAGT
TAGC-3′ and reverse primer 5′-ATTTGTGCAGGC
CAAGCTGC-3′ for rs280519; forward primer 5′-TCAC
CAGGCACTTGTTGTCC-3′ and reverse primer
5′-CGGCTTCCAGCATGTGTATG-3′ for rs2304256; and
forward primer 5′-ACATTTCCCCCTGCCTACAC-3′ and
reverse primer 5′-TTACAGACATGCGCCACCAC-3′ for
rs280523. The other constituents of the PCR mixture were
the same as described above. The amplification protocol
comprised initial denaturation at 95°C for 2 min, followed
by 30 cycles of denaturation at 95°C for 30 s, annealing at
64°C (rs280496, rs280519, and rs280523) or 62°C
(rs2304256) for 30 s, and extension at 72°C for 30 s and
final extension at 72°C for 5 min. The PCR products were
digested with Bsl I (New England BioLabs Inc., Beverly,
MA, USA) for rs280496, Hpy99 I (New England BioLabs
Inc.) for rs280519, Bsm I (New England BioLabs Inc.) for
rs2304256, and BsiE I (New England BioLabs Inc.) for
rs280523. The digests were then separated on a 2% agarose
gel as described above.
Fig. 2 Locations of the genotyped tag SNP sites in TYK2 in the
International HapMap (upper) and iHap (lower) data. The horizontal
bars in the middle indicate the genomic sequence of TYK2. Blue
vertical bars indicate the positions of all SNP sites. A yellow rectangle
represents the positions of a linkage disequilibrium block. A list and
the locations of candidate tag SNPs are shown in the lower right
position using Haploview 4.0 software. Red inverted triangles indicate
the genotyped tag SNPs sites in this study, and their names are
presented above each inverted triangle
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Two tag SNPs in TYK2, which showed a close association
of susceptibility to CD and were located within the same
linkage disequilibrium block (Fig. 2), were utilized to infer
the haplotype structure as well as to analyze the haplotype
frequency using the SNP Alyze 7.0 standard software
package (Dynacom Inc., Yokohama, Japan) to emphasize
the variability and to enhance the power of detecting allelic
association of rare variants [33, 34].
Statistical Analysis
Differences in age and gender between UC or CD patients
and control subjects were evaluated by an unpaired
Student’s t test and a chi-square test, respectively, using
the SPSS 17 (SPSS Japan Inc., Tokyo, Japan) and Prism 5
(GraphPad Software Inc., San Diego, CA, USA) statistical
software packages. The frequencies of the expected alleles
were calculated from those of the observed genotypes
according to the Hardy–Weinberg equilibrium. The fre-
quencies of the observed and expected alleles were
compared by the chi-square test with Yates’ correction
using the SNP Alyze 7.0 standard software package. The
frequencies and distributions of alleles, genotypes, haplo-
types, and diplotypes were statistically compared between
UC or CD patients and control subjects by the chi-square
test and logistic regression analysis using Prism 5 and SPSS
17. Subsequently, a comparison of the genetic risk factors
between the statistically significant genotype of STAT3 and
diplotype of TYK2 for susceptibility to CD was carried out
by a multivariate logistic regression analysis using SPSS
17. The odds ratio (OR) with 95% confidence interval (CI)
was calculated using SPSS 17. A P value of less than 0.05
was considered to be statistically significant.
Results
Association of Tag SNPs in STAT3 with Susceptibility
to IBD
The frequencies and distributions of alleles and genotypes
at the three tag SNPs in STAT3 were identified and
compared between UC or CD patients and control subjects
(Tables II and III, respectively). The C allele at rs8074524
SNP, G allele at rs2293152 SNP, and A allele at rs957970
SNP are major alleles, whereas the other alleles are minor
alleles (Table II). The distributions of these tag SNPs in
STAT3 among IBD patients and control subjects corre-
sponded well to the Hardy–Weinberg equilibrium, thus
implying that the subject base has a homogeneous genetic
background.
The frequencies of the C allele and its homozygous C/C
genotype at rs2293152 in CD patients were significantly
higher than those in control subjects (45.2% vs. 33.3%,
P=0.007 and 22.9% vs. 8.5%, P=0.001, respectively). No
significant differences were observed in the frequency of
other alleles and genotypes between patients and control
subjects.
Table II Distributions of Polymorphic Alleles at the Genotyped Tag SNP Sites in STAT3 and TYK2 Among Study Subjects
Gene SNP Allele Number (%) of alleles in Allele comparison
a Number (%) of alleles in Allele comparison
a
UC Control P value CD Control P value
STAT3 rs8074524 C 144 (64.3) 253 (63.3) 0.759 106 (63.9) 253 (63.3) 0.892
T 80 (35.7) 147 (36.7) 60 (36.1) 147 (36.7)
rs2293152 G 151 (66.2) 267 (66.7) 0.894 91 (54.8) 267 (66.7) 0.007
C 77 (33.8) 133 (33.3) 75 (45.2) 133 (33.3)
rs957970 A 116 (51.8) 218 (54.5) 0.652 84 (50.6) 218 (54.5) 0.397
G 108 (48.2) 182 (45.5) 82 (49.4) 182 (45.5)
TYK2 rs280496 C 201 (89.7) 362 (90.5) 0.784 144 (86.7) 362 (90.5) 0.187
G 23 (10.3) 38 (9.5) 22 (13.3) 38 (9.5)
rs280519 A 136 (60.7) 224 (56.0) 0.261 109 (65.7) 224 (56.0) 0.034
G 88 (39.3) 176 (44.0) 57 (34.3) 176 (44.0)
rs2304256 C 156 (69.6) 262 (65.5) 0.311 129 (77.7) 262 (65.5) 0.004
A 68 (30.4) 138 (34.5) 37 (23.3) 138 (34.5)
rs280523 G 207 (92.4) 370 (92.5) 0.968 154 (92.8) 370 (92.5) 0.911
A 17 (7.6) 30 (7.5) 12 (7.2) 30 (7.5)
Total number of alleles 228 400 166 400
aEach allele was compared to another allele using a chi-square test.
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to IBD
The frequencies and distributions of alleles and genotypes
at the four tag SNPs in TYK2 were identified and compared
between UC or CD patients and control subjects (Tables II
and III, respectively). The C allele at rs280496 SNP, A
allele at rs280519 SNP, C allele at rs2304256 SNP, and
G allele at rs280523 SNP are major alleles, whereas other
alleles are minor alleles (Table II). The distributions of
these tag SNPs in TYK2 among IBD patients and control
subjects corresponded well to the Hardy–Weinberg equi-
librium. The frequencies of the A allele and its homozygous
A/A genotype at rs280519 in CD patients were significantly
higher than those in control subjects (65.7% vs. 56.0%,
P=0.034 and 44.6% vs. 31.5%, P=0.037, respectively).
Likewise, the frequencies of the C allele and its homozy-
gous C/C genotype at rs2304256 in CD patients were also
significantly higher than those in control subjects (77.7%
vs. 65.5%, P=0.004 and 62.7% vs. 43.0%, P=0.003,
respectively). In contrast, the frequency of the C/A
heterozygous genotype at rs2304256 was significantly
lower in CD patients in comparison to that in control
subjects (30.1% vs. 45.0%, P=0.021).
Association of Haplotypes and Diplotypes of TYK2
with Susceptibility to CD
Subsequently, four haplotypes composed of these two tag
SNPs (rs280519 and rs2304256), which displayed a
significant association with CD susceptibility and were
located within the same linkage disequilibrium block, were
constructed and identified using the SNPAlyze 7.0 standard
software package (Table IV). A logistic regression analysis
revealed the frequency of a Hap 1 haplotype (A allele at
rs280519 SNP and C allele at rs2304256 SNP) to
significantly increase in CD patients in comparison to that
in control subjects (65.7% vs. 55.3%, P=0.023,
OR=1.549). In contrast, the frequency of a Hap 2
haplotype (G allele at rs280519 SNP and A at rs2304256
SNP) was significantly decreased in CD patients in
comparison to that in control subjects (22.3% vs. 33.7%,
P=0.007, OR=0.563).
Furthermore, eight diplotypes composed of four haplo-
types were identified (Table V). A logistic regression
analysis showed that the frequency of the CD patients
possessing a Hap 1/Hap 1 diplotype was significantly
higher than that of the control subjects (44.6% vs. 30.5%,
P=0.024, OR=1.833). In contrast, the frequency of the CD
Gene SNP Genotype Number (%) of genotypes in Genotype comparison
a
CD Control OR (95% CI) P value
STAT3 rs8074524 C/C 34 (41.0) 75 (37.5) 1.156 (0.686–1.951) 0.586
C/T 38 (45.8) 103 (51.5) 0.795 (0.476–1.329) 0.382
T/T 11 (13.3) 22 (11.0) 1.236 (0.570–2.680) 0.591
rs2293152 G/G 27 (32.5) 84 (42.0) 0.666 (0.389–1.141) 0.139
G/C 37 (44.6) 99 (49.5) 0.821 (0.491–1.372) 0.451
C/C 19 (22.9) 17 (8.5) 3.196 (1.566–6.523) 0.001
rs957970 A/A 19 (22.9) 55 (27.5) 0.783 (0.430–1.424) 0.423
G/A 46 (55.4) 108 (54.0) 1.059 (0.633–1.772) 0.827
G/G 18 (21.7) 37 (18.5) 1.220 (0.648–2.296) 0.538
TYK2 rs280496 C/C 61 (73.5) 162 (81.0) 0.650 (0.356–1.187) 0.161
C/G 22 (26.5) 38 (19.0) 1.538 (0.842–2.807) 0.161
G/G 0 0 ––
rs280519 A/A 37 (44.6) 63 (31.5) 1.749 (1.034–2.959) 0.037
A/G 35 (42.2) 98 (49.0) 0.759 (0.453–1.272) 0.295
G/G 11 (13.2) 39 (19.5) 0.631 (0.306–1.302) 0.212
rs2304256 C/C 52 (62.7) 86 (43.0) 2.224 (1.315–3.716) 0.003
C/A 25 (30.1) 90 (45.0) 0.527 (0.305–0.909) 0.021
A/A 6 (7.2) 24 (12.0) 0.571 (0.225–1.454) 0.240
rs280523 G/G 71 (85.5) 170 (85.0) 1.044 (0.506–2.155) 0.907
G/A 12 (14.5) 30 (15.0) 0.958 (0.464–1.976) 0.907
A/A 0 0 ––
Total number of subjects 83 200
Table III Distribution of Gen-
otypes at the Tag SNP Sites in
STAT3 and TYK2 Between CD
Patients and Control Subjects
OR odds ratio, CI confidence
interval
aEach genotype was compared
to other genotypes combined
using a logistic regression
analysis
J Clin Immunol (2009) 29:815–825 821patients having a Hap 1/Hap 2 diplotype was significantly
lower than that of the control subjects (24.1% vs. 36.5%,
P=0.045, OR=0.552). The results of the diplotype analysis
regarding the Hap 1 haplotype of TYK2 coincided well with
those of the haplotype analysis between CD patients and
control subjects; however, a Hap 2/Hap 2 diplotype showed
no statistically significant lack of susceptibility to CD
(Table V).
Gene–Gene Interaction Between STAT3 and TYK2 for
Susceptibility to CD
The gene–gene interaction between STAT3 and TYK2 was
analyzed between CD patients and control subjects. A
multivariate logistic regression analysis indicated that two
variable genetic factors, the C/C genotype at rs2293152
SNP in STAT3 and the Hap 1/Hap 1 diplotype of TYK2,
independently contributed to susceptibility to CD (P=
0.002, OR=3.113, 95% CI=1.515–6.399 and P=0.030,
OR=1.783, 95% CI=1.042–3.053, respectively; Table VI).
Furthermore, with regard to the gene–gene combination
effect of STAT3 genotype and TYK2 diplotype for suscep-
tibility to CD, a multivariate logistic regression analysis
showed the OR to significantly increase (7.486, P=0.0008,
95% CI=2.310–24.261) in the individuals possessing both
the C/C genotype at rs2293152 SNP in STAT3 and the Hap
1/Hap 1 diplotype of TYK2 in comparison to that in the
individuals possessing the other genotypes (Table VII).
Discussion
This study is the first demonstration of the single-marker
association of STAT3 and TYK2 polymorphisms with CD
susceptibility in the Japanese population, although meta-
analyses using GWA data previously indicated that STAT3
and TYK2 appear to be the genetic determinants of CD in
the European and North American populations [9, 10, 14].
Furthermore, STAT3 is associated with only CD, but not
UC, in the Japanese population by a candidate gene-based
association study, thereby supporting the meta-analysis of
the GWA data in populations of European and North
American ancestry [9].
The presence of the C allele and its homozygous C/C
genotype at rs2293152 SNP in STAT3 conferred suscepti-
bility to CD. CD- and UC-susceptible rs744166 SNP, which
was identified by GWA studies [9, 12, 14], was not
analyzed in this study because this SNP was not selected
as a genotyped tag SNP by the iHap software program.
Because rs744166 and rs957970 SNPs are located within
the same linkage disequilibrium block (Fig. 1)a n d
rs957970 SNP was not associated with susceptibility to
Haplotype SNP Number (%) of haplotypes in Haplotype comparison
a
rs280519 rs2304256 CD Control OR (95% CI) P value
Hap 1 A C 109 (65.7) 221 (55.3) 1.549 (1.063–2.256) 0.023
Hap 2 G A 37 (22.3) 135 (33.7) 0.563 (0.370–0.857) 0.007
Hap 3 G C 20 (12.0) 41 (10.3) 1.199 (0.680–2.117) 0.530
Hap 4 A A 0 3 (0.7) ––
Total number of haplotypes 166 400
Table IV Distributions of Hap-
lotypes of TYK2 Between CD
Patients and Control Subjects
OR odds ratio, CI confidence
interval
aEach haplotype was compared
to other haplotypes combined
using a logistic regression
analysis
Diplotype Number (%) of diplotypes in Diplotype comparison
a
CD Control OR (95% CI) P value
Hap 1/Hap 1 37 (44.6) 61 (30.5) 1.833 (1.082–3.105) 0.024
Hap 1/Hap 2 20 (24.1) 73 (36.5) 0.552 (0.309–0.986) 0.045
Hap 1/Hap 3 15 (18.1) 24 (12.0) 1.618 (0.801–3.268) 0.180
Hap 1/Hap 4 0 2 (1.0) ––
Hap 2/Hap 2 6 (7.2) 23 (11.5) 0.600 (0.235–1.531) 0.285
Hap 2/Hap 3 5 (6.0) 15 (7.5) 0.791 (0.278–2.251) 0.660
Hap 2/Hap 4 0 1 (0.5) ––
Hap 3/Hap 3 0 1 (0.5) ––
Total number 83 200
Table V Distributions of Dip-
lotypes of TYK2 Between CD
Patients and Control Subjects
OR odds ratio, CI confidence
interval
aEach diplotype was compared
to other diplotypes combined
using a logistic regression
analysis
822 J Clin Immunol (2009) 29:815–825CD in this study, rs744166 SNP may not be associated with
CD in the Japanese population. The difference in suscep-
tibility to CD at the SNP site between Caucasian and
Japanese subjects can be attributed to genetic background,
although STAT3 may contribute to the same mechanisms of
the immunopathogenesis of CD in both Caucasian and
Japanese patients.
The presence of the A allele and its homozygous A/A
genotype at rs280519 SNP in TYK2, the C allele and its
homozygous C/C genotype at rs2304256 SNP in TYK2, the
Hap 1 haplotype (A allele at rs280519 SNP and C allele at
rs2304256 SNP) of TYK2, and its homozygous Hap 1/Hap
1 diplotype of TYK2 showed susceptibility to CD. CD-
susceptible rs12720356 SNP, which was identified by GWA
studies [10], was not analyzed in this study because this
SNP was not selected as a genotyped tag SNP by the iHap
software program. Although rs280519 and rs2304256
SNPs, which were examined in this study, are located
within the same linkage disequilibrium block, rs12720356
SNP does not belong to any linkage disequilibrium blocks
(Fig. 2). Furthermore, because rs280496 SNP, nearby
rs12720356 SNP, was not associated with susceptibility to
CD in this study, rs12720356 SNP may thus not be
associated with CD in the Japanese population. This
disparity can be also attributed to genetic differences
between Caucasian and Japanese individuals, although
TYK2 may contribute to the same immunopathogenesis in
both Caucasian and Japanese CD patients.
In addition, the presence of both the C/C genotype at
rs2293152 in STAT3 and the Hap 1/Hap 1 diplotype of
TYK2 independently contributed to the pathogenesis of CD
and remarkably increased the odds ratio for CD, thus
indicating an approximately 7.5-fold increase in suscepti-
bility to CD in this study, although such CD patients
account for only approximately 13% (11 of 83=13.3% in
Table VII) of the genetic variance observed in CD. These
findings imply that STAT3 and TYK2 are genetic determi-
nants for the predisposition to the onset and/or development
of CD in Japanese individuals. However, this study
population was relatively small, and further studies on a
larger number of Japanese subjects and on other ethnicities
are necessary to confirm the association between the STAT3
and TYK2 polymorphisms and CD. Additional studies are
needed because different populations will often have
different allele frequencies and haplotype structures.
Recent GWA studies on the IL-23/IL23R signaling
pathway have shifted the focus to the IL-23 cytokine
[6–12]. After IL-23 binds to the receptor, which comprises
IL23R and IL12RB1 [35], IL-23 signaling may induce the
activation of JAK2 in IL23R as well as TYK2 in IL12RB1
because the IL-12RB1 and IL-23R require TYK2 [16], thus
resulting in the phosphorylation of STAT3 as well as
STAT1, STAT4, and STAT5 in activated macrophages and
dendritic cells [35]. The signaling cascade eventually leads
to the differentiation of CD4
+ (naive) Tcells into Th17 cells
[17, 20–22]. Th17 cells produce IL-17A, IL-17F, and IL-
22, which are involved in the first line of the host defense
by controlling the immune responses [22]. Indeed, the
expression of IL-12, IL-23, STAT3, IL-17, and IL-22 has
been reported to increase in the lamina propria of the
Table VI Gene–Gene Interaction Between STAT3 Genotype and TYK2 Diplotype for Susceptibility to CD
Factor Factor comparison
a
OR (95% CI) P value
C/C genotype at rs2293152 in STAT3 3.113 (1.515–6.399) 0.002
Hap 1/Hap 1 diplotype of TYK2 1.783 (1.042–3.053) 0.030
OR odds ratio, CI confidence interval
aFactors were statistically analyzed by a multivariate logistic regression analysis
Table VII The Gene–Gene Combination Effect of STAT3 Genotype and TYK2 Diplotype for Susceptibility to CD
Factor Number (%) of Factor comparison
a
CD Control OR (95% CI) P value
C/C genotype at rs2293152 in STAT3 and Hap 1/Hap 1 of TYK2 11 (13.3) 4 (2.0) 7.486 (2.310–24.261) 0.0008
Other genotypes 72 (86.7) 196 (98.0)
OR odds ratio, CI confidence interval
aFactors were statistically analyzed by a multivariate logistic regression analysis
J Clin Immunol (2009) 29:815–825 823intestinal mucosa in CD patients [36–41]. Taken together,
the IL-23/IL23R signaling pathway is central to the
inflammation leading to CD and modifies an individual’s
risk of developing CD. For these reasons, it may be
speculated that the polymorphisms of STAT3 and TYK2,
especially the C/C genotype at rs2293152 in STAT3 and the
Hap 1/Hap 1 diplotype of TYK2, may affect the gain-
of-function of both STAT3 and TYK2, thus altering the
efficiency of the IL-23/IL23R signaling pathway. These
changes can lead to the perpetuation of the chronic
intestinal inflammatory process, thereby resulting in the
onset and/or development of CD.
Conclusions
As TYK2 and STAT3 appear to be the genetic determinants
of CD in the Japanese population, the combination
polymorphism of TYK2 and STAT3 may be useful as a
new DNA-based diagnostic biomarker for identifying high-
risk individuals susceptible to CD. Finally, STAT3 and
TYK2 may be good target molecules for the development of
novel drugs in the future.
Acknowledgments We are grateful to the physicians, patients, and
volunteers who participated in this study. This work was supported by
a research grant from the Non Profit Organization Aimed to Support
Community Medicine Research in Nagasaki.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Fiocchi C. Inflammatory bowel disease: etiology and pathogene-
sis. Gastroenterology. 1998;115:182–205.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med.
2002;347:417–29.
3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of
inflammatory bowel disease. Nature. 2007;448:427–34.
4. Cho JH. The genetics and immunopathogenesis of inflammatory
bowel disease. Nat Rev Immunol. 2008;8:458–66.
5. Budarf ML, Labbé C, David G, Rioux JD. GWA studies:
rewriting the story of IBD. Trend Genet. 2009;25:137–46.
6. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverbergy MS, Daly
MJ, et al. A genome-wide association study identifies IL23R as an
inflammatory bowel disease gene. Science. 2006;314:1461–3.
7. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett
A, et al. Genome-wide association study identifies new suscepti-
bility loci for Crohn disease and implicates autophagy in disease
pathogenesis. Nat Genet. 2007;39:596–604.
8. The Wellcome Trust Case Control Consortium. Genome-wide
association study of 14, 000 cases of seven common diseases and
3, 000 shared controls. Nature. 2007;447:661–78.
9. Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T,
Prescott NJ, et al. Genome-wide association study defines more
than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet.
2008;40:955–62.
10. Wang K, Zhang H, Kugathasan S, Annese V, Bradfield JP, Russell
RK, et al. Diverse genome-wide association studies associate the
IL12/IL23 pathway with Crohn disease. Am J Hum Genet.
2009;84:399–405.
11. Lobo A, Forbes A, Sanderson J, Jewell DP, Mansfield JC,
Deloukas P, et al. Genetic determinants of ulcerative colitis induce
the ECM1 locus and five loci implicated in Crohn’s disease. Nat
Genet. 2008;40:710–2.
12. Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T, et
al. Replication of signals from recent studies of Crohn’s disease
identifies previously unknown disease loci for ulcerative colitis.
Nat Genet. 2008;40:713–5.
13. Abraham C, Cho JH. IL-23 and autoimmunity: new insights into
the pathogenesis of inflammatory bowel disease. Annu Rev Med.
2009;60:97–110.
14. Mathew CG, Schreiber S, the IBSEN study group, Franke A,
Balschum T, Karlsen TH, et al. Sequence variants in IL10,
APRC2 and multiple other loci contribute to ulcerative colitis
susceptibility. Nat. Genet. 2008;40:1319–23.
15. Shimoda K, Kato K, Aoki K, Matsuda T, Miyamoto A, Shibamori
M, et al. Tyk2 plays a restricted role in IFNα signaling, although
it is required for IL-12-mediated T cell function. Immunity.
2000;13:561–71.
16. Murray PJ. The JAK-STAT signaling pathways: input and output
integration. J Immunol. 2007;178:2623–9.
17. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O’Shea
JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles
of STAT4. Immunol Rev. 2004;202:139–56.
18. Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L.
Interleukin-6-type cytokine signalling through the gp130/Jak/
STAT pathway. Biochem J. 1998;334:297–314.
19. Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K,
Tsuchiya S, et al. Human tyrosine kinase 2 deficiency reveals its
requisite roles in multiple cytokine signals involved in innate and
acquired immunity. Immunity. 2006;25:745–55.
20. Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th17 axis:
therapeutic targets for autoimmune inflammation. Curr Opin
Immunol. 2006;18:670–5.
21. Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, Luger
D, et al. Cutting edge: NKT cells constitutively express IL-23
receptor and RORγt and rapidly produce IL-17 upon receptor
ligation in an IL-6-independent fashion. J Immunol. 2008;
180:5167–71.
22. Nakamura R, Shibata K, Yamada H, Shimoda K, Nakayama K,
Yoshikai Y. Tyk2-signaling plays an important role in host defense
against Escherichia coli through IL-23-induced IL-17 production
by γδ T cells. J Immunol. 2008;181:2071–5.
23. Lennard-Jones JE. Classification of inflammatory bowel disease.
Scand J Gastroenterol Suppl. 1989;170:2–6.
24. Podolsky DK. Inflammatory bowel disease (1). N Eng J Med.
1991;325:928–37.
25. Podolsky DK. Inflammatory bowel disease (2). N Eng J Med.
1991;325:1008–16.
26. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The
Montreal classification of inflammatory bowel disease: controver-
sies, consensus, and implications. Gut. 2006;55:749–53.
27. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid)
versus sulphasalazine in the treatment of active ulcerative colitis:
a randomised trial. BMJ. 1989;298:82–6.
28. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a
Crohn’s disease activity index. National Cooperative Crohn’s
Disease Study. Gastroenterology. 1976;70:439–44.
29. Akira S, Nishio Y, Inoue M, Wang X-J, Wei S, Matsusaki T, et al.
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3
824 J Clin Immunol (2009) 29:815–825p91-related transcription factor involved in the gp130-mediated
signaling pathway. Cell. 1994;77:63–71.
30. Firmbach-Kraft I, Byers M, Shows T, Dalla-Favera R, Krolewski
JJ. tyk2, prototype of a novel class of non-receptor tyrosine kinase
genes. Oncogene. 1990;5:1329–36.
31. The International HapMap Consortium. A second generation
human haplotype map of over 3.1 million SNPs. Nature. 2007;
449:851–61.
32. SongCM,YeoBH,TantosoE,YangY,LimYP,LiK-B,etal.iHAP
—integrated haplotype analysis pipeline for characterizing the
haplotype structure of genes. BMC Bioinformatics. 2006;7:525.
33. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-
resolution haplotype structure in the human genome. Nat Genet.
2001;29:229–32.
34. Johnson GCL, Esposito L, Barratt BJ, Smith AN, Heward J, Di
Genova G, et al. Haplotype tagging for the identification of
common disease genes. Nat Genet. 2001;29:233–7.
35. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J,
et al. A receptor for the heterodimeric cytokine IL-23 is composed
of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J
Immunol. 2002;168:5699–708.
36. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, et
al. Blockade of interleukin 6 trans signaling suppresses T-cell
resistance against apoptosis in chronic intestinal inflammation:
evidence in Crohn disease and experimental colitis in vivo. Nat
Med. 2000;6:583–8.
37. Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T,
Zeuzem S, et al. Expression of interleukin-12-related cytokine
transcripts in inflammatory bowel disease: elevated interleukin-
23p19andinterleukin-27p28inCrohn’sdiseasebutnotinulcerative
colitis. Inflamm Bowel Dis. 2005;11:16–23.
38. Mudter J, Weigmann B, Bartsch B, Kiesslich R, Strand D, Galle
PR, et al. Activation pattern of signal transducers and activators of
transcription (STAT) factors in inflammatory bowel diseases. Am
J Gastroenterol. 2005;100:64–72.
39. Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, et al.
Both iL-12p70 and IL-23 are synthesized during active Crohn’s
disease and are down-regulated by treatment with anti-IL-12p40
monoclonal antibody. Inflamm Bowel Dis. 2006;12:9–15.
40. Wolk K, Witte E, Hoffmann U, Doecke W-D, Endesfelder S,
Asadullah K, et al. IL-22 induces lipopolysaccharide-binding
protein in hepatocytes: a potential systemic role of IL-22 in
Crohn’s disease. J Immunol. 2007;178:5973–81.
41. Hölttä V, Klemetti P, Sipponen T, Westerholm-Ormio M,
Kociubinski G, Salo H, et al. IL-23/IL-17 immunity as a hallmark
of Crohn’s disease. Inflamm Bowel Dis. 2008;14:1175–84.
J Clin Immunol (2009) 29:815–825 825